Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

Fig. 2

LAG3 is associated with a better prognosis in mesothelioma. Overall survival analysis using the Kaplan–Meier method for LAG3 mRNA (A) and immunohistochemical expression (B) groups in MPM. The log-rank test demonstrated that elevated LAG3 mRNA and immunohistochemical expression correlated with a better prognosis (mRNA: HR = 0.5820, 95% CI 0.3678–0.9211, P = 0.0178, protein: HR = 0.4291, 95% CI 0.2043–0.9012, P = 0.0476). HR with 95% CI was reported using a univariate Cox regression model. LAG3 mRNA expression is from TCGA, and immunohistochemical expression is from our cohort. HR, hazard ratio; CI, confidence interval; MPM, malignant pleural mesothelioma; TCGA, The Cancer Genome Atlas

Back to article page